Skip to main content
. 2017 Apr 17;8(25):41227–41241. doi: 10.18632/oncotarget.17167

Figure 5. AKT1, PTEN and S6K gene expression in human breast cancers before and 24 hrs after epirubicin exposure.

Figure 5

(A) Box plots of gene expression of PTEN, AKT1 and S6K normalized to RPLP2 in human breast cancer samples, before and 24 hrs after the first epirubicin dose, from patients in the dose dense trial. (B) Box plots from the same patient cohort as in (A), but depicted separately for estrogen receptor (ER) positive and ER negative breast cancers. *p<0.05